DAMORA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $6.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.90M, a 329.82% increase year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was $3.60M, a 854.11% increase year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$182.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $230.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $1.10M.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$3.14M.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$3.33M, a 171.47% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $4.67M, a 1602.92% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $6.49M 10-Q · filed 2026-08-10 | $6.31M derived: sum of 3 quarters · filed 2026-08-10 | $6.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $3.60M 10-Q · filed 2026-05-12 | $3.42M derived: sum of 2 quarters · filed 2026-05-12 | $3.65M derived: sum of 3 quarters · filed 2026-05-12 | $4.32M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $48.00K derived: sum of 2 quarters · filed 2026-03-19 | $722.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.10M 10-K · filed 2026-03-19 |
| 2025-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $904.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.28M 10-Q · filed 2025-11-06 | $182.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $674.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.05M 10-Q · filed 2026-08-10 | -$48.00K derived: sum of 3 quarters · filed 2026-08-10 | -$1.05M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $377.00K 10-Q · filed 2026-05-12 | -$722.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.72M derived: sum of 3 quarters · filed 2026-05-12 | -$1.31M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.10M derived: sum of 2 quarters · filed 2026-03-19 | -$1.69M derived: sum of 3 quarters · filed 2026-03-19 | -$3.14M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$591.00K derived: sum of 2 quarters · filed 2025-11-06 | -$2.04M 10-Q · filed 2025-11-06 | -$5.82M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $411.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.04M 10-Q · filed 2025-08-05 | -$4.82M derived: sum of 3 quarters · filed 2025-08-05 | -$6.01M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$1.45M 10-Q · filed 2025-05-08 | -$5.23M derived: sum of 2 quarters · filed 2025-05-08 | -$6.42M derived: sum of 3 quarters · filed 2025-05-08 | -$7.56M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$4.97M derived: sum of 2 quarters · filed 2025-03-19 | -$6.11M derived: sum of 3 quarters · filed 2025-03-19 | -$3.33M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$2.33M derived: sum of 2 quarters · filed 2024-11-01 | $445.00K 10-Q · filed 2024-11-01 | $1.19M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.64M 10-Q · filed 2024-08-12 | $2.39M derived: sum of 3 quarters · filed 2024-08-12 | $4.51M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $2.78M 10-Q · filed 2024-04-29 | $3.53M derived: sum of 2 quarters · filed 2024-04-29 | $5.66M derived: sum of 3 quarters · filed 2024-04-29 | $6.38M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.88M derived: sum of 2 quarters · filed 2024-03-08 | $3.60M derived: sum of 3 quarters · filed 2024-03-08 | $4.67M 10-K · filed 2024-03-08 |
| 2022-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.86M derived: sum of 2 quarters · filed 2023-11-06 | $3.92M 10-Q · filed 2023-11-06 | $3.20M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $729.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $1.79M 10-Q · filed 2023-07-31 | $1.07M derived: sum of 3 quarters · filed 2023-07-31 | $1.69M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $1.06M 10-Q · filed 2023-04-28 | $342.00K derived: sum of 2 quarters · filed 2023-04-28 | $959.00K derived: sum of 3 quarters · filed 2023-04-28 | $333.00K derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$719.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$102.00K derived: sum of 2 quarters · filed 2023-03-09 | -$728.00K derived: sum of 3 quarters · filed 2023-03-09 | $274.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $617.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$9.00K derived: sum of 2 quarters · filed 2022-11-08 | $993.00K 10-Q · filed 2022-11-08 | -$131.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$626.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $376.00K 10-Q · filed 2022-07-29 | -$748.00K derived: sum of 3 quarters · filed 2022-07-29 | $1.25M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | $1.00M 10-Q · filed 2022-04-29 | -$122.00K derived: sum of 2 quarters · filed 2022-04-29 | $1.88M derived: sum of 3 quarters · filed 2022-04-29 | -$251.00K derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | -$1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $876.00K derived: sum of 2 quarters · filed 2022-02-17 | -$1.25M derived: sum of 3 quarters · filed 2022-02-17 | -$2.14M 10-K · filed 2022-02-17 |
| 2020-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$129.00K derived: sum of 2 quarters · filed 2021-11-04 | -$1.02M 10-Q · filed 2021-11-04 | -$321.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$2.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$3.02M 10-Q · filed 2021-08-05 | -$2.32M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$890.00K 10-Q · filed 2021-05-04 | -$192.00K derived: sum of 2 quarters · filed 2021-05-04 | ||
| 2019-12-31 | $698.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $1.61M 10-K · filed 2021-03-29 | ||
| 2019-09-30 | $908.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |